Butterfly Network, Inc. (BFLY) Stock Price & How to Invest

Last updated November 2026

Short answer

Butterfly Network (NYSE: BFLY) is a medical-device company selling handheld, semiconductor-based ultrasound probes plus attached software, and it now also licenses its ultrasound chip to outside partners. Investing in it is a bet on point-of-care ultrasound and that chip business scaling while the company is still unprofitable and richly valued relative to roughly $123M of trailing revenue. Third-quarter 2026 revenue jumped about 52% and management raised its outlook, yet the stock has fallen about 39% over three months; as of November 20, 2026 it was still up about 47% year to date, for a market value near $1.5B.

BFLY stock price

As of 2026-11-20, Butterfly Network, Inc. (BFLY) last closed at $5.40, up 103.8% over the past year. Over the past 52 weeks it has traded between $2.65 and $9.93.

BFLY last close
$5.40
1 day
-7.69%
1 month
-23.94%
1 year
+103.77%
52-week range
$2.65 to $9.93
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Butterfly Network, Inc.'s investor relations page. Walnut is informational, not investment advice.

BFLY key stats

At $5.40 on November 20, 2026, Butterfly Network, Inc. (BFLY) has a market cap of $1.4B.

Market cap
$1.4B
Price to book
7.8
Beta
2.12

Market cap, P/E and yield are measured at the $5.40 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Butterfly Network, Inc. (BFLY)?

The last two weeks for Butterfly Network, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • BFLY closed at $5.40 on November 20, 2026, down 11.2% over the past five trading days (from $6.08).

Butterfly Network, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Butterfly Network, Inc. (BFLY) latest quarter

Butterfly Network reported revenue of $32.6 million for Q3 2026, up 52% from a year earlier (Butterfly Network, Oct 29, 2026).

Revenue
$32.6 million
up 52% from a year earlier
Diluted EPS (GAAP)
-$0.05
n/a
Product
$15.6 million
up 7% from a year earlier

Source: Butterfly Network Q3 2026 results, Oct 29, 2026. Full earnings breakdown

What does Butterfly Network, Inc. (BFLY) do?

Butterfly Network designs and sells handheld ultrasound systems built on its proprietary Ultrasound-on-Chip technology, which replaces the traditional piezoelectric crystals in an ultrasound machine with a semiconductor sensor. That lets a single probe (the flagship iQ3) image the whole body and connect to a phone or tablet, and the company layers on subscription software, cloud storage, and AI tools that push clinicians toward higher-margin recurring revenue. Customers include hospitals, clinics, medical schools, and increasingly international and lower-resource settings where a $2,000-to-$5,000-range device is far cheaper than a cart-based system. A newer line, embedded revenue, comes from partners that build the chip into their own products.

The investment picture is classic emerging medtech: real and accelerating growth against persistent losses, offset by a cash cushion of about $122M at the end of September 2026. Q1 2026 revenue rose about 25% year over year, Q2 about 40% to roughly $32.6M, and Q3 (reported October 29) about 52% to roughly $32.6M, beating the top of guidance. In the third quarter embedded revenue reached about $11.1M, up more than 1,000% on partnerships including Midjourney, Merge Labs and Bridge Neurotech, while core point-of-care ultrasound grew about 5% and international revenue slipped about 5% to $5.1M. Gross margin hit a record of about 73%, the adjusted EBITDA loss narrowed about 85% to roughly $1.2M, quarterly cash burn was about $2.4M, and the net loss of about $12.8M, or $0.01 per share, beat the roughly $0.04 loss analysts expected. Management raised its 2026 revenue and adjusted EBITDA guidance, achieved FedRAMP authorization for federal buyers, signed 15 enterprise deals, and targets cash-flow breakeven in 2028; it also filed a $150M shelf and at-the-market equity program, and its fourth-quarter guidance implies revenue could dip from the third quarter. In mid-November the CEO said he expects chip revenue to grow larger than the ultrasound device business.

The stock has been extremely volatile. It fell after the report despite the beat, and at about $5.51 on November 20, 2026 it was down roughly 39% over three months, though still up about 47% year to date and about 138% over the past year. It trades at about 12 times trailing sales. The bull case rests on embedded chip deals, software mix, and AI driving the model toward profitability; the bear case is that competition, revenue lumpiness, and dilution keep margins and the share price under pressure.

What's driving Butterfly Network, Inc. (BFLY)?

1. Software and recurring-revenue mix shift

Software and other services revenue grew roughly 68% year over year in Q1 2026 to about $12M and makes up a larger share of the total. Because software carries much higher gross margins than probes, this mix shift, together with embedded chip revenue, is the main lever behind company gross margin reaching a record of about 73% in Q3 2026 and the adjusted-EBITDA loss narrowing to about $1.2M.

2. iQ3 probe and hardware refresh cycle

The higher-priced iQ3 probe, launched domestically and then internationally, has lifted average selling prices. New hardware refreshes drive device replacement demand, though they also make quarterly revenue lumpy as sales are tied to launch timing and channel adoption; in Q3 2026 core point-of-care ultrasound grew only about 5% and international revenue fell about 5%.

3. Embedded chip, AI and new markets

Butterfly is embedding AI-guided acquisition and interpretation tools and licensing its Ultrasound-on-Chip to other companies. Embedded revenue reached about $11.1M in Q3 2026, up more than 1,000%, with partners including Midjourney, Merge Labs and Bridge Neurotech (which is developing a non-invasive brain-computer interface on the chip), and the CEO has said he expects chip revenue to outgrow the device business. Mendaera made its Focalist system compatible with the chip, the Edward Via College of Osteopathic Medicine signed a long-term alliance for ultrasound education, FedRAMP authorization opens federal buyers, and a home and community care effort is expected to produce first revenue in Q4 2026.

4. Cost discipline and path toward breakeven

The company has cut cash burn sharply, to about $2.4M in Q3 2026, with trailing free cash flow of roughly negative $7M, and its quarterly net loss has held near $13M in each quarter of 2026 while revenue grew. Management targets cash-flow breakeven in 2028. Reaching sustainable profitability depends on holding operating expenses roughly flat while revenue compounds in the 20%-plus range.

What are the risks to Butterfly Network, Inc. (BFLY)?

Butterfly remains unprofitable, with trailing net losses of roughly $54M against about $123M of revenue as of September 2026, so it depends on its roughly $122M cash balance and, potentially, future capital raises; the $150M shelf and at-the-market equity program filed in Q3 2026 could dilute shareholders if used. The point-of-care ultrasound market is competitive, with GE HealthCare, Philips, Clarius, Exo, and others fielding rival handheld devices, which can pressure pricing and adoption. Revenue is lumpy because it leans on hardware launch cycles, large institutional orders and a small number of embedded partners; fourth-quarter guidance implies a possible sequential decline. The stock trades near 12 times trailing sales and 8 times book value and has fallen about 39% in three months, showing how sharp drawdowns can be. Insiders sold shares in November 2026. Newer projects such as the brain-computer interface work are early and unproven, and regulatory, reimbursement, and clinical-adoption dynamics add further uncertainty to the timeline for profitability.

What is the Butterfly Network, Inc. (BFLY) forecast?

6 analysts publish price targets on BFLY, averaging $11.17 as of November 2026, or +106.9% against the $5.40 share price on November 20, 2026. The published targets run from $10.00 to $15.00, a moderate spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BFLY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is BFLY a buy or a sell?

We give no verdict on Butterfly Network, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Software and recurring-revenue mix shift. Software and other services revenue grew roughly 68% year over year in Q1 2026 to about $12M and makes up a larger share of the total. The most optimistic published target, $15.00, assumes this works close to its best case.

The case against. Butterfly remains unprofitable, with trailing net losses of roughly $54M against about $123M of revenue as of September 2026, so it depends on its roughly $122M cash balance and, potentially, future capital raises; the $150M shelf and at-the-market equity program filed in Q3 2026 could dilute shareholders if used. The most pessimistic target, $10.00, is roughly what BFLY is worth if this bites instead.

Read the full bull and bear case on BFLY, including what would have to change to break either one. Walnut is not an investment adviser.

Has Butterfly Network, Inc. (BFLY) split its stock?

No. Butterfly Network, Inc. (BFLY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Butterfly Network, Inc. (BFLY) valued?

Market cap, P/E and dividend yield at today's price are in the BFLY key stats above. The business figures below come from Butterfly Network, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$123M
  • Q3 2026 revenue growth: ~52% YoY (~$32.6M)
  • Gross margin (TTM / Q3 2026): ~70% / ~73%
  • Net loss (TTM): ~$54M
  • Cash / debt (Sep 2026): ~$122M / ~$18M

As of November 2026: As of November 20, 2026, Butterfly closed near $5.51 for a market cap of about $1.5B, roughly 12 times its $123M of trailing revenue, down from about 18 times in October as the shares fell. Analysts on average expect about $125M of 2026 revenue and about $150M in 2027, with fourth-quarter consensus near $33.8M of revenue and a loss of about $0.02 per share. The average analyst target in Yahoo Finance's data is about $11, from 6 analysts.

Who competes with Butterfly Network, Inc. (BFLY)?

Large medical-device OEMs

GE HealthCare (Vscan Air) and Philips (Lumify) sell handheld or portable ultrasound backed by major distribution, service networks, and hospital relationships, competing on brand trust and integrated workflows especially in cardiac and vascular imaging.

Handheld point-of-care specialists

Clarius, Exo (Exo Iris), Mindray (TE Air), and EchoNous (Kosmos) are focused handheld-ultrasound challengers competing directly with the iQ3 on price, AI guidance, image quality, and subscription terms.

Traditional cart-based ultrasound

Incumbent cart and console ultrasound systems from GE, Philips, Canon, Samsung Medison, and others remain the imaging standard in many settings; Butterfly competes by offering a far cheaper, portable alternative for point-of-care use.

What stocks are similar to Butterfly Network, Inc. (BFLY)?

Other names that sit close to BFLY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Butterfly Network, Inc. (BFLY)

There are three common ways to get BFLY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BFLY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BFLY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Butterfly Network, Inc. (BFLY)

BFLY pairs genuine revenue growth and a differentiated ultrasound-on-chip platform with continuing losses and a demanding valuation, making it a high-risk, growth-stage story, not a settled profitable business. The third quarter brought record gross margin of about 73%, a near-breakeven adjusted EBITDA loss and raised 2026 guidance, but also a new at-the-market equity program, and the shares closed near $5.51 on November 20, 2026, well off their October levels.

More on Butterfly Network, Inc. (BFLY)

Whether BFLY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BFLY a buy or a sell?, and where the stock could go from here in the BFLY stock forecast.

For income investors, whether BFLY pays a dividend and how the payout looks is covered in does BFLY pay a dividend? And to weigh BFLY against a peer, read the full side-by-side comparisons: BFLY vs GEHC and BFLY vs GE.

Wondering how BFLY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Butterfly Network, Inc.

Ask Walnut's AI anything about BFLY and see how it fits what you own.

FAQ

What does Butterfly Network do?

+

It makes handheld ultrasound probes built on a proprietary Ultrasound-on-Chip semiconductor, letting a single device image the whole body when plugged into a phone or tablet. It also sells subscription software, cloud storage, and AI tools that add recurring revenue on top of the hardware, and it earns embedded revenue from partners that build its chip into their own products.

Is Butterfly Network profitable?

+

No. As of September 2026 the company was still posting net losses, with trailing losses of roughly $54M against about $123M of revenue. It has held its quarterly net loss near $13M, narrowed the Q3 2026 adjusted EBITDA loss to about $1.2M and cut quarterly cash burn to about $2.4M, and it targets cash-flow breakeven in 2028. Analysts still expect a loss for full-year 2026.

How fast is Butterfly growing?

+

Revenue grew about 25% year over year in Q1 2026 to roughly $26.5M, about 40% in Q2 to roughly $32.6M, and about 52% in Q3 to roughly $32.6M, with the Q3 jump driven by embedded chip revenue of about $11.1M. Management raised its full-year 2026 guidance after the third quarter, and analysts now expect about $125M of 2026 revenue, roughly 28% growth.

What is the iQ3 probe?

+

The iQ3 is Butterfly's flagship third-generation handheld ultrasound probe, offered at a higher price point than earlier models. Its domestic and international launches have raised average selling prices and helped lift international revenue.

Who are Butterfly Network's main competitors?

+

In handheld point-of-care ultrasound it competes with GE HealthCare's Vscan Air, Philips' Lumify, Clarius, Exo, Mindray, and EchoNous. It also competes indirectly with traditional cart-based ultrasound systems from large imaging OEMs.

How much cash does Butterfly have?

+

At the end of September 2026 the company reported roughly $122M in cash and equivalents against about $18M of debt, for a net cash position of over $100M. That balance funds a multi-year runway at its recent quarterly burn of about $2.4M, and the company also filed a $150M shelf and at-the-market equity program that it could use to raise more.

Why is BFLY stock so volatile?

+

It is a small, unprofitable growth-stage medtech whose share price has swung sharply, from about $2.33 to $10.21 over the 52 weeks to November 2026. It jumped about 22% in one day in September 2026 after Needham started coverage at Buy, then fell after its strong Q3 report and was down about 39% over the three months to November 20. Lumpy revenue, a high valuation relative to sales, possible dilution, and sensitivity to growth and margin surprises all amplify the volatility.

How did Butterfly Network do in its latest quarter?

+

For Q3 2026 (ended September 30, reported October 29), Butterfly reported revenue of about $32.6M, up roughly 52% from a year earlier and above the top of its guidance, with record gross margin near 73%. The net loss was about $12.8M, or $0.01 per share, narrower than the roughly $0.04 loss analysts expected, its fifth straight beat. Management raised 2026 revenue and adjusted EBITDA guidance.

How has BFLY stock performed in 2026?

+

BFLY closed at about $5.51 on November 20, 2026, up roughly 47% year to date and about 138% over the past year, though it was down about 18% over the prior month and about 39% over three months. Needham and Canaccord Genuity both started coverage at Buy with $10 targets in September and October 2026. Past performance says nothing certain about future returns.

How can I research investing in BFLY?

+

You can review its SEC filings, quarterly results, revenue mix, cash burn, and competitive position, then weigh the growth story against its losses and valuation. Walnut is not an investment adviser, and this page is descriptive information, not a recommendation to buy or sell.

What is Butterfly's embedded chip business?

+

Butterfly supplies its Ultrasound-on-Chip semiconductor to partners that build it into their own devices. Embedded revenue was about $11.1M in Q3 2026, up more than 1,000% from a year earlier, with partners including Midjourney, Merge Labs and Bridge Neurotech. The company does not break out each partner's contribution, and the CEO said in November 2026 that he expects chip revenue to exceed the ultrasound device business over time.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Butterfly Network, Inc.'s investor relations page or your broker before making investment decisions.